---
title: "Peijia Medical Chair and CEO to Boost Stake with HK$15 Million Share Purchase"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/280555286.md"
description: "Peijia Medical Ltd. announced that its chairman and CEO, Dr. Yi Zhang, plans to purchase shares worth up to HK$15 million starting March 26, 2026, to increase his stake in the company. This move reflects his confidence in the company's value and growth potential. The company assures that it will maintain sufficient public float under Hong Kong listing rules. The latest analyst rating for Peijia Medical (HK:9996) is a Hold with a price target of HK$6.50."
datetime: "2026-03-25T22:39:30.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/280555286.md)
  - [en](https://longbridge.com/en/news/280555286.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/280555286.md)
---

# Peijia Medical Chair and CEO to Boost Stake with HK$15 Million Share Purchase

### Claim 30% Off TipRanks Premium

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential

Peijia Medical Ltd. ( (HK:9996) ) just unveiled an announcement.

Peijia Medical Limited reported that its chairman, chief executive officer and executive director, Dr. Yi Zhang, plans to increase his stake in the company by purchasing shares on the open market through a controlled corporation starting March 26, 2026. The planned share purchases will have a total consideration not exceeding HK$15 million and will be executed in compliance with applicable laws and regulations.

According to the company, Dr. Zhang views the additional investment as a demonstration of his confidence in Peijia Medical’s intrinsic value, development prospects and growth potential, and he may further increase his holdings in future. The company also stressed that, even after the shareholding increase, it continues to maintain sufficient public float under Hong Kong listing rules and advised shareholders and potential investors to exercise caution when trading its shares.

The most recent analyst rating on (HK:9996) stock is a Hold with a HK$6.50 price target. To see the full list of analyst forecasts on Peijia Medical Ltd. stock, see the HK:9996 Stock Forecast page.

**More about Peijia Medical Ltd.**

Peijia Medical Limited is a Hong Kong-listed medical company focused on developing and commercializing healthcare products and technologies. The group operates through its subsidiaries and is led by executive director and chief executive officer Dr. Yi Zhang, who also serves as chairman of the board of directors.

**Average Trading Volume:** 915,893

**Technical Sentiment Signal:** Sell

**Current Market Cap:** HK$3.73B

For a thorough assessment of 9996 stock, go to TipRanks’ Stock Analysis page.

### Related Stocks

- [09996.HK](https://longbridge.com/en/quote/09996.HK.md)

## Related News & Research

- [Arna Pharma and Slate Run complete JV for new US company](https://longbridge.com/en/news/286581059.md)
- [VERTANICAL’s VER-01 gains FDA breakthrough status for low back pain](https://longbridge.com/en/news/286901967.md)
- [Trump's settlement in IRS lawsuit includes dropping tax cases, audits](https://longbridge.com/en/news/286992353.md)
- [03:15 ETElliott Management Statement on Nippon Express Holdings, Inc.](https://longbridge.com/en/news/287021791.md)
- [Major Holdings Sets June Board Meeting to Approve Annual Results and Consider Final Dividend](https://longbridge.com/en/news/286541211.md)